StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) company profile

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.60−0.06 (-3.61%)

Close on Nov 17, 2026Market cap $13.19MP/E –Yield –

About Lipocine

Pharmaceutical Preparations, SIC 2834

Lipocine Inc. is a biopharmaceutical company focused on developing oral formulations of poorly bioavailable drugs using its proprietary lipidic delivery technology platform. Its primary development programs target neurological and psychiatric central nervous system disorders, liver disease, and hormone supplementation. The company's approved product is TLANDO, an oral testosterone replacement therapy for adult males with hypogonadism. It also develops pipeline candidates such as LPCN 1154 for postpartum depression, alongside programs for major depressive disorder, essential tremor, epilepsy, and obesity management. Its customers and commercial partners include pharmaceutical companies that license and distribute its products.

The company operates in the United States and has licensing and distribution partnerships spanning the United States, Canada, South Korea, Brazil, and the Gulf Cooperation Council countries. Lipocine maintains its principal executive offices in Salt Lake City, Utah.

Summary of the business section of Lipocine's latest annual report, written by StockData.

Company profile

Company

Legal name
Lipocine Inc.
Headquarters
Salt Lake City, X1
Address
675 Arapeen Drive, Suite 202 84108
Phone
(801) 994-7383
Employees
14, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Tanner LLP, Salt Lake City, Utah

Stock & identifiers

Ticker
LPCN
Exchange
Nasdaq
IPO date
Oct 22, 2013
Shares outstanding
8M, Aug 3, 2026
Public float
$16.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-17 reverse, May 12, 2023
SEC CIK
1535955
CUSIP
53630X203
ISIN
US53630X2036
FIGI
BBG0029L1X69
Share class FIGI
BBG0029L1Y76
LEI
549300RXPEQXOJXVBI10
EIN
99-0370688

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mahesh V. PatelChief Executive Officer, Director400,207
Krista FogartyPrincipal Accounting Officer1,727
John W. HiguchiDirector299,843
Michael GrissingerDirector–
Jill M. JeneDirector–
Richard Dana OnoDirector14,125
Spyros PapapetropoulosDirector21,739
Jeffrey Arvin FinkDirector6,562

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$986.34K$1.05M$488.43K$119–
FY2024$761.77K$754.74K$377.19K$72–
FY2023$860.34K$720.11K$353.39K$41–
FY2022$883.85K$538.78K$324.99K$40–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Mahesh V. Patel
President and Chief Executive Officer
$584.78K$89.42K$292.39K$19.75K$986.34K+29%
Krista Fogarty
Principal Accounting Officer and Corporate Controller
$275.31K$62.16K$96.36K$12.13K$445.96K+31%
Nachiappan Chidambaram
Senior Vice President, Research and Development
$331.20K$69.78K$115.92K$14.00K$530.90K+28%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“of December 31, 2025, we had 14 full-time employees, and we also utilize the services of consultants on a regular basis.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?